Clinical results of intraperitoneal hyperthermic perfusion combined with surgery in patients with peritoneal recurrence from gastric cancer

Six patients with peritoneal recurrence after radical operation for gastric cancer were treated by an intraperitoneal hyperthermic perfusion (IPHP) combined with surgery (IPHP group). Immediately after surgery, a 2-hour IPHP was performed, using a perfusate containing 10 micrograms/ml of MMC, warmed at the inflow temperature of 46.5 +/- 1.1 degree C. Within the same period of time, 5 patients with intra-abdominal recurrent gastric cancer (control group) were treated by an intraperitoneal administration of MMC 10 mg combined with surgery. These 11 patients had malignant peritoneal effusion and, although in 3 of the control group, ascitic effusion did re-accumulate rapidly soon after surgery, the 6 patients of IPHP group did not re-accumulate post-hyperthermically. The average survival duration of IPHP group is 13.6 +/- 10. 6 months, whereas that for controls is 3.0 +/- 2.1 months. Again, the survival rate for IPHP group surpassed that for controls at p = 0.012 and p = 0.008, in a generalized Wilcoxon method and Logrank method, respectively. Post-hyperthermically, hypoproteinemia and thrombocytopenia occurred transitorily. These results show that IPHP using MMC combined with surgery is a safe, reliable treatment for patients with peritoneal recurrence due to gastric cancer.     

Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer

BACKGROUND: Peritoneal recurrence is a major cause of death in advanced gastric cancer. Although many kinds of chemotherapy intended to prevent peritoneal recurrence of gastric cancer have been evaluated, few have been successful. Few studies have assessed the clinical significance of continuous hyperthermic peritoneal perfusion in peritoneal recurrence. METHODS: From 1992 to 1999, a total of 124 patients with advanced gastric cancer with tumors invading deeper than the serosa but with no peritoneal metastasis underwent potentially curative gastrectomy and were enrolled in this study. Prophylactic continuous hyperthermic peritoneal perfusion (P-CHPP) was performed in 45 patients younger than 65 years old and without comorbidity who gave informed consent. Seventy-nine patients who did not meet the inclusion criteria represented the control group. After reconstruction of the alimentary tract, P-CHPP was carried out for 40 minutes with 150 mg cisplatin, 15 mg mitomycin C, and 150 mg etoposide in 5 to 6 L physiologic saline maintained at 42 degrees C to 43 degrees C. The surgical results, recurrent pattern, and postoperative morbidity were assessed by univariate and multivariate analysis. RESULTS: When compared with patients not undergoing P-CHPP, patients treated by P-CHPP had higher incidences of respiratory failure (73% vs 19%; P <.0001) and renal failure (7% vs 0%; P <.03). Neither 5-year survival (49% vs 56%) nor the patterns of recurrence (peritoneal, hematogenous, and lymphatic) were affected by P-CHPP. CONCLUSIONS: P-CHPP by our methods had no efficacy as prophylactic treatment for peritoneal recurrence induced by gastric cancer. New therapeutic strategies, such as chemosensitivity assessment, are necessary to obtain good therapeutic results with CHPP.     

��ǻ�Ȼ��ƶԷ���θ���������󸴷����ٴ�����

目的 探讨进展期胃肠道癌手术切除后腹腔复发转移的防治方法。方法 对５３例进展期胃肠道癌病人分组行围手术期持续腹腔温热化疗,并对其化疗术后１、２、３年生存率对照研究。结果 ２７例病人施腹腔化疗后１、２、３年生存期分别为８８．４６％,８０．７６％,６９．２３％明显高于对照组的８４．６１％,６１．５％及４６．２％,且并发症与副作用无差异。结论 腹腔温热化疗对进展期胃肠道癌术后复发良好的防治作用。     

Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor

Desmoplastic small round cell tumor (DSRCT) is a rare disease of children, adolescents, and young adults that begins and spreads on the peritoneal surfaces. Desmoplastic small round cell tumor usually presents with diffuse abdominal metastatic disease similar in gross appearance to carcinomatosis. To date, very aggressive treatment programs have yielded dismal outcomes. Here we present 2 cases of DSRCT that were treated with aggressive surgical excision followed by intraoperative continuous hyperthermic peritoneal perfusion using cisplatin. These are the first pediatric case reports of DSRCT being treated with continuous hyperthermic peritoneal perfusion, a procedure usually used in treatment of adult carcinomatosis.     

顺铂联合持续热灌注治疗胃癌腹腔种植转移的临床疗效观察

目的 探讨顺铂（DDP）联合持续热灌注治疗胃癌腹腔种植转移的临床疗效.方法 2009年2月至2012年2月间治疗的84例胃癌腹腔种植转移患者,随机分为观察组和对照组,每组各42例.观察组采用DDP联合腹腔持续热灌注治疗,对照组采用单独DDP腹腔灌注治疗.观察并记录两组患者腹水控制情况、不良反应发生情况.对患者进行随访,统计生存情况.结果 观察组和对照组总有效率分别为71.4％和50.0％,两组比较差异有统计学意义（P＜0.05）.两组中位生存期分别为10.3个月和6.0个月.两组不良反应发生率差异无统计学意义（P＞0.05）.结论 DDP联合持续热灌注治疗胃癌腹腔种植转移的临床疗效好,不良反应少,值得临床上进一步推广.     

腹腔热灌注治疗在胃癌腹腔转移中的应用

腹腔热灌注化疗是防治腹腔恶性肿瘤,尤其胃癌术后腹腔复发和肝转移的一项重要措施,其综合利用局部化疗、热疗和大容量化疗液对腹腔的机械灌洗作用,具有药代动力学及流体动力学优势,能有效清除游离癌细胞及微小癌灶,防治术后腹腔转移和肝转移.     

Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.

Fifteen patients with far-advanced gastric cancer were given surgical treatment followed by intraperitoneal hyperthermic perfusion (IPHP) with mitomycin C (MMC) and misonidazole (MIS), a thermosensitizing drug. Immediately after extensive resection of the abdominal tumors, a 2-hour IPHP was performed at the inflow temperature of 44.7 to 48.7 C, using equipment designed for treatment of cancerous peritoneal seeding as a closed circuit, and under hypothermic general anesthesia at 30 to 31 C. In nine of the 15 patients with peritoneal seeding and/or ascites, cancerous ascites was absent after this treatment. In all cases, repeated cytologic examinations of the lavage from Douglas's pouch were negative. The postoperative courses were uneventful except for Patients 1 and 10, in whom slight leakage occurred. All patients were discharged and are in good health at the time of this writing, 7.2 +/- 4.6 months after the treatment. The Case 4 Patient recently died in a traffic accident. In all patients, transient hepatic dysfunction and hypoproteinemia occurred after the operation. This extensive surgery combined with IPHP using MMC and MIS was well tolerated and is a safe antitumor treatment for gastric cancer with peritoneal dissemination. Neurotoxicity due to MIS was nil.     

胃癌术后腹腔热灌注联合静脉化疗的应用研究

目的研究胃癌术后腹腔热灌注化疗联合静脉化疗的治疗效果。方法140例胃癌根治术后患者随机分为腹腔热灌注组(n=72)和静脉化疗组(n=68)。腹腔热灌注组患者在静脉化疗同时应用腹腔热灌注化疗,观察两组术后并发症、不良反应、术后生存率及腹腔复发率。结果两组在术后并发症及不良反应无显著性差异。术后3、5年生存率腹腔热灌注组和静脉化疗组分别为86.1%、60.2%和58.3%、29.4%(P<0.05);术后3、5年腹腔复发率分别为5.6%、27.8%和20.6%、53%(P<0.05)。结论胃癌术后腹腔热灌注联合静脉化疗可有效控制复发和转移,提高胃癌术后病人的生存率和生存质量。     

Prospective study of peritoneal recurrence after curative surgery for gastric cancer

BACKGROUND: Peritoneal carcinomatosis is a common cause of failure after surgery for gastric cancer. The present longitudinal study was designed to evaluate the incidence and potential predictors of peritoneal recurrence after curative resection for gastric cancer. METHODS: Four hundred and forty-one patients who underwent potentially curative resections for gastric cancer in three surgical centres between 1988 and 1996 were evaluated. All patients were followed using a standard protocol following discharge from hospital. The correlation between tumour recurrence and clinicopathological variables was studied by univariate and multivariate analyses. RESULTS: Gastric cancer recurred in 215 (49 per cent) of 441 patients. Peritoneal recurrence was observed in 77 patients (17 per cent), locoregional recurrence in 96 patients and haematogenous recurrence in 75. Multivariate logistic regression analysis of factors associated with peritoneal recurrence identified diffuse-mixed histological type (relative risk (RR) 4.31, P < 0.001), infiltration of the serosa (RR 3.36, P = 0.001), lymph node involvement (RR 2.67, P = 0.023) and tumour size (RR 1.11, P = 0.050) as significant independent variables. In the diffuse-mixed histological subtype, the 5-year cumulative risk of peritoneal recurrence was 12 per cent in the absence of serosal invasion, and 69 per cent in patients with infiltration of the serosa; in the intestinal subtype, the cumulative risk in patients with serosa-negative and -positive tumours was 4 and 21 per cent respectively. CONCLUSION: Radical surgery offers a low probability of cure in patients with diffuse-mixed type of gastric cancer and involvement of the serosa, due to a high risk of peritoneal recurrence. These patients might benefit from adjuvant therapies to prevent peritoneal carcinomatosis.     

Experimental studies on continuous hyperthermic peritoneal perfusion in the treatment for peritoneal metastases of cancer

As a preliminary study to apply thermotherapy or thermochemotherapy to the treatment of peritoneal dissemination of gastric cancer, a continuous hyperthermic peritoneal perfusion (CHPP) was carried out for the experimental peritoneal dissemination of Donryu rats inoculated with AH100B ascitic hepatoma cells (AH100B cells). Firstly, the cytotoxicity of heat on AH100B cells was studied. No cytotoxicity was observed at 37 degrees C, but mild cytotoxicity was noted at 41.5 degrees C, and marked rise in cytotoxicity was seen at 42.5 degrees C. These cytotoxicity increased with addition to Mitomycin C and prolongation of the heating time. Next, on the 1st, 5th and 10th day after inoculation of AH100B cells, the Donryu rats were treated as follows: Group 1; CHPP (37 degrees C for 1 hr), Group 2; CHPP (41.5 degrees C for 1 hr), Group 3; (42.5 degrees C for 1 hr), Group 4; CHPP (41.5 degrees C for 1 hr)+MMC 1 mg/kg (intraperitoneal administration immediately after completion of CHPP). Group 5; MMC 1 mg/kg (intraperitoneal administration). Death within 48 hours after perfusion occurred in one rat of the 41.5 degrees C perfusion group and 14 rats of the 42.5 degrees C perfusion group. Comparison of the survival time on these groups showed the most remarkable life-prolonging effect in CHPP (41.5 degrees C)+MMC group. On the basis of the results of this study, the CHPP method combined with anti-cancer chemotherapy is considered to be an useful treatment for peritoneal dissemination of cancer.     

腹腔热低渗液灌注及术后动脉插管化疗治疗胃癌的效果观察

目的 探讨进展期胃癌手术切除后腹腔及肝转移的防治方法。方法 对１４６例进展胃癌病人分组行腹腔热低渗液灌注及动脉插管化疗,并对其腹腔转移率、肝转移率及３年生存率对照研究。结果 治疗组的腹腔转移率、肝转移率低于对照组,３年生存率高于对照组。结论腹腔热低渗液灌注及动脉插管化疗对进展期胃癌术后复发有良好的防治作用。     

奥沙利铂用于胃癌术后早期腹腔热灌注化疗的临床观察

目的观察进展期胃癌根治术后早期给予奥沙利铂(L-OHP)行腹腔热灌注化疗(CHIP)的不良反应及疗效。方法将83例进展期胃癌随机分为CHIP组和对照组,应用SPSS13.0分析并发症、复发率、转移率和无瘤生存率。CHIP组共37例,术后第1天给予L-OHP 100 mg/m2行CHIP,1次/d,4次为1疗程。对照组46例给予常规处理。结果两组严重并发症发生率差异无统计学意义。CHIP组的2~3年无瘤生存率明显高于对照组,差异有统计学意义。结论进展期胃癌术后早期给予L-OHP行CHIP,对提高2~3年无瘤生存率有明显疗效,而且方法简单、安全、实用。     

术中腹腔内温热化疗对进展期胃癌的临床疗效研究

目的 探讨术中腹腔内温热化疗（IPHC）治疗进展期胃癌的临床疗效。方法 1998年至2001年手术切除的T3、T4胃癌118例。将无腹膜转移的96例作为预防性研究组，其中42例行IPHC，54例单纯手术作对照，随访观察术后生存情况和IPHC对腹膜复发的预防作用；将有腹膜转移的22例作为治疗性研究组，其中10例行IPHC，12例作对照，观察术后生存期。同时对全组IPHC（52例）和单纯手术者（66例）进行总的生存分析比较。结果 预防性研究组中，IPHC者术后1、2、4年生存率为85．7％、81．0％和63．9％，优于单纯手术者（77．3％、61．0％和50．8％）。C0x模型提示，IPHC是T3、T4胃癌的独立预后因素；术后腹膜复发率10．3％，低于单纯手术者的34．7％。治疗性研究组中，IPHC者术后生存时间（中位生存期10个月）较单纯手术者（中位生存期5个月）长。全组IPHC病例总的术后1、2、4年生存率（76．9％、69．2％和55．2％）高于单纯手术的病例（66．2％、49．7％和41．4％）。结论 IPHC可提高B、L胃癌患者的生存率，延长生存期。     

Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases

Background: Intraperitoneal (i.p.) metastases pose a special problem for surgical treatment because of their multiplicity and microscopic size. This study was designed to examine the feasibility and safety of i.p. hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer. Methods: Fifteen patients with metastatic colon cancer were treated. All patients underwent cytoreductive procedures leaving only residual i.p. metastases <1 cm in diameter. All patients had received prior systemic chemotherapy, but their disease had progressed. Intraperitoneal chemotherapy was administered through three large catheters (28 French) using a closed system of two pumps, a heat exchanger, and two filters. After the patient’s abdominal temperature reached 41°C, 45–60 mg of MMC was circulated intraperitoneally for 1 h. Results: The majority of patients had various anastomoses: small bowel (n=11), large bowel (n=5), and urologic (n=5). No anastomotic complications occurred in any of the patients. One patient experienced severe systemic MMC toxicity, which caused cytopenia and respiratory depression. In all patients the carcinoembryonic antigen (CEA) level decreased after surgery and IPHP. Median follow-up was 10 months, and recurrence was defined as an elevation in CEA level. Disease recurred in three patients within 5 months, and disease recurred in seven other patients over the next 3 months; one patient remains clinically free of disease after 8 months. Conclusion: Our data suggest that IPHP is a safe palliative method of treatment for patients with peritoneal carcinomatosis. The median patient response duration of 6 months may warrant consideration of a repeat IPHP procedure at that time. Presented at the 46th Annual Cancer Symposium of The Society of Surgical Oncology, Los Angeles, March 18–21, 1993.     

胃癌并腹膜转移腹腔镜姑息性切除术后腹腔热灌注化疗的安全性及疗效

目的 探讨腹腔镜胃癌并腹膜转移姑息性切除术联合腹腔热灌注化疗的安全性与疗效.方法 回顾性分析2010年3月至2013年10月间在南方医科大学南方医院普通外科接受腹腔镜姑息性切除术后腹腔热灌注化疗（100 mg顺铂、1000 mg氟尿嘧啶、2000 ml生理盐水）的37例胃癌并腹膜转移患者的临床病理资料,观察患者近期疗效及不良反应发生情况.结果 18例患者获完全缓解,4例获部分缓解,8例疾病稳定,7例疾病进展.肿瘤总缓解率为59.5％（22/37）,Kamofsky功能状态评价获显著改善者6例,改善者13例,稳定者10例,进展者8例,改善与稳定患者占78.4％（29/37）.严重不良反应（Ⅲ/Ⅳ级）3例（8.1％）,其中腹痛2例（Ⅲ级）,恶心呕吐1例（Ⅲ级）.结论 胃癌并腹膜转移腹腔镜姑息性切除术后应用顺铂联合氟尿嘧啶方案的腹腔热灌注化疗是安全的,对延缓肿瘤进展具有一定作用.     

进展期胃癌术中腹腔热灌注化疗的效果分析

目的:分析进展期胃癌术中腹腔热灌注化疗的效果。方法:选取94例接受胃癌根治术的患者,按照随机数字表分为观察组及对照组,各47例,观察组接受术中腹腔热灌注化疗,对照组仅接受单纯根治性手术,对比两组患者的疗效和并发症情况。结果:观察组CR 8例,PR 26例,有效率72.3%;对照组CR 3例,PR 15例,有效率38.3%,观察组有效率显著高于对照组(P0.05)。2组患者术后均出现血液指标异常、发热、血压下降、心率上升及其他并发症,均经对症处理后在7 d内恢复正常,其各项指标异常、并发症发生率无明显统计学差异(P0.05)。观察组患者1年、2年及3年存活率分别为85.1%、57.4%及29.8%,均显著高于对照组(P0.05)。结论:进展期胃癌术中腹腔热灌注化疗较传统胃癌根治术具有更好的疗效,且无明显不良反应,疗效及安全性均可靠。     

胃癌患者术中腹腔内温热灌注化疗的临床研究

目的探讨胃癌根治术中一次性腹腔温热灌注化疗的临床疗效。方法将术中行一次性腹腔温热灌注化疗的55例胃癌患者(治疗组)与未行此方法治疗的101例患者(对照组)的腹腔游离癌细胞检出率及预后等情况进行对比。结果治疗组的温热灌注液游离癌细胞检出率为7.3%,对照组冲洗液的癌细胞检出率为30.7%(P<0.01)。治疗组与对照组术后两年内腹腔复发率分别为14.5%和38.6%(P<0.01)。治疗组术后1、2、3年生存率分别为100%、80.0%和61.8%,对照组则为96.0%、52.5%和35.6%,两组2、3年生存率比较,差异有显著性意义(P<0.01)。结论一次性腹腔温热灌注化疗简便、高效、安全,具有杀灭腹腔游离癌细胞的作用,可降低患者术后腹腔复发率和提高生存率。     

Carcinoembryonic antigen levels in the peritoneal cavity: Useful guide to peritoneal recurrence and prognosis for gastric cancer

At the time of laparotomy, peritoneal washings were collected from 155 gastric cancer patients and the levels in carcinoembryonic antigen (CEA) determined. The CEA levels in peritoneal washings were statistically independent of those in sera and could more reliably predict the presence of peritoneal metastasis than a cytologic study. Peritoneal recurrence was seen in 14 of 118 patients after curative operation. Of the 14 patients, 10 (71%) had elevated levels of CEA (100 ng/g protein) at surgery. Of these 10 cases, 2 of the tumors were classified as stage IB and 4 had no serosal invasion. Only one patient with peritoneal metastasis and a low CEA level was free from relapse more than 1 year after operation. Kaplan-Meier's analysis showed that a high CEA level in peritoneal washings was a predictor of poor prognosis in patients who underwent either curative or noncurative resection. A proportional hazards regression analysis showed that a high CEA level in peritoneal washings was statistically significant in terms of predicting a shorter interval until peritoneal recurrence (p=0.0002) and for survival (p=0.0001). The CEA level in peritoneal washings is therefore of value as an indicator of peritoneal recurrence and prognosis.

---

Resumen Se obtuvieron lavados peritoneales en el momento de la laparotomía en 155 pacientes con cáncer gástrico y se determinaron los niveles de antígeno carcinoembrionario (CEA). Los niveles de CEA en los lavados peritoneales aparccieron estadísticamente independientes de aquellos en el suero y podrían ser mejores indicadores de la presencia de metástasis peritoneales que el estudio citológico. La recurrencia peritoneal se presentó en 14 de 118 pacientes luego de operación con propósito curativo. De los 14 pacientes, 10 (71%) presentaban altos niveles de CEA (100 ng/g de proteina) en el momento de la cirugía. De los 10 casos, 2 fueron clasificados como estado IB y 4 no presentaban invasión serosa. Sólo un paciente con metástasis peritoneales que tenía un bajo nivel de CEA, apareció libre de recurrencia mas de un año después de la operación. El análisis de Kaplan-Meier demostró que altos niveles de CEA en los lavados peritoneales podria ser un factor de pronóstico pobre tanto en los pacientes sometidos a resección con propósito curativo como en aquellos sometidos a resección no curativa. Un análisis de regresión demostró que el alto nivel de CEA en el lavado peritoneal are estadístincamente significativo en cuanto a un intervalo más corto para la metástasis peritoneal (p=0.0002) y sobrevida (p=0.0001). El nivel de CEA en el lavado peritoneal es valioso como indicador de recurrencia peritoneal y de pronóstico.

---

Résumé Le péritoine a été lavé et l'antigène carcinoembryonnaire (ACE) a été dosé dans le liquide recueilli lors de la laparotomie chez 155 patients ayant un cancer gastrique lors de leur laparotomie. Le taux d'ACE dans ces lavages était statistiquement indépendant de ceux dosés dans la sércuse, et pourrait être un facteur pronostique plus fidèle que l'examen cytologique en ce qui concerne la possibilité de métastases péritonéales. La récidive péritonéale s'est développée chez 14 de 118 patients après une exérèse estimée curative. Chez ces 14 patients, 10 (71%) avaient des niveaux élevés d'ACE (100 ng/g protéine) au moment de la chirurgie. De ces 10 cas, deux ont été classés stage IB et quatre n'avaient ps d'envahissement séreux. Seul un patient ayant une métastase péritonéale, qui avait un taux assez bas d'ACE, n'a pas récidivé plus d'un an après son intervention. Une analyse des taux selon la méthode de Kaplan-Meier a démontré qu'un taux élevé d'ACE était un facteur de mauvais pronostic à lo fois chez les patients ayant une résection curative et chez ceux qui avaient eu une résection à titre palliatif. Une analyse de régression démontrait qu'un taux élevé d'ACE dans le liquide de lavage péritonéal était un facteur de récidive précoce (p<0.0002) et de survie plus courte (p<0.0001). Le taux d'ACE dans le liquide de lavage péritonéal est corrélé avec la récidive et mauvais pronostic des cancers gastriques.

     

Magnitude of serosal changes predicts peritoneal recurrence of gastric cancer

BACKGROUND: Peritoneal dissemination is the most frequent mode of recurrence in patients with gastric cancer. We tried to identify factors that predict peritoneal recurrence with high sensitivity. STUDY DESIGN: Clinical and pathologic data from 587 consecutive patients with gastric cancer were reviewed retrospectively. The stepwise Cox proportional hazards regression model was used to assess the prognostic significance of the magnitude of serosal changes. Multiple stepwise logistic regression analysis was used to determine factors associated with peritoneal recurrence in 375 patients who underwent curative resection. RESULTS: The 5-year survival rate of patients with S2 disease (greatest dimension of macroscopic serosal changes >/= 2.5 cm) was 18%, which was worse than S0 (no serosal changes) and S1 disease (macroscopic serosal changes < 2.5 cm)(p < 0.001). Patients with S0 tumors who underwent curative resection had the best 5-year survival rate. Multivariate analyses indicated that the magnitude of serosal changes was an independent prognostic factor for survival both overall and after curative resection. Logistic regression analysis showed that peritoneal recurrence was more than four times as likely with S2 than with S0 or S1 tumors. The sensitivity for predicting peritoneal recurrence was 79%; the sensitivity of cytologic examination was 38%. CONCLUSIONS: Magnitude of serosal changes is easy to measure intraoperatively and predicts peritoneal recurrence of gastric cancer with greater sensitivity than conventional peritoneal lavage cytology.     

θ���������ڸ�ǻ�ȹ�ע���Ƶ�Ӧ��̽��

目的探讨胃癌术后早期腹腔热灌注化疗的可行性、安全性及短期疗效。方法对2002年7月至2003年12月对15例进展期胃癌和1例吻合口复发癌,术中行根治或姑息性切除;对直径≥0.5cm的腹腔内转移灶用电刀减量戮灭。术后第1天开始,每日腹腔热灌注化疗1次,每次60～90min,一般4次为1疗程,计做64次。结果循环通畅率96.9%(62/64),治疗时间内腹腔内温度80%达到41℃以上,各出水管温度均超过41℃,并保持60～90min。并发症及毒副反应有:轻度腹腔感染2例,吻合口漏1例,腹痛4例,恶心呕吐2例,转氨酶轻度升高1例。随访6～27个月,术后每3个月复查1次B超或CT,腹腔转移3例,腹腔转移率为18.8%,1例术后6个月死于全身广泛转移,另1例术后13个月死于腹腔转移及肝转移。最长1例随访时间为27个月,现仍存活。结论术后早期腹腔热灌注化疗安全,腹腔内温度较均匀,可多次进行,并发症少及毒副反应小,有利于胃癌术后腹腔内较小的残余癌或游离癌细胞的杀灭。